Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gruppo Oncologico del Nord-Ovest
The objective of this trial is to determine whether Cetuximab and radiation preceded by an induction chemotherapy, may be superior to an established chemoradiation program for HNC (RTOG regimen, Adelstein DJ J.Clin.Oncol. 2003;21:92-98).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\> 18 years of age
Histologically or cytologically confirmed diagnosis of HNSCC
Stage III/IV, not suitable for surgery (definitive cure rate improbable, technically unresectable or medical contraindication for surgery)
At least one uni-dimensional measurable lesion either by CT scan or MRI
Signed written informed consents prior to beginning protocol
Specific procedures:
Tumor tissue available for immunohistochemical staining of EGFR expression and HPV
Life expectancy of \> 3 months at study entry
ECOG Performance Status of \<2 at study entry.
Effective contraception if risk of conception exists.
